Luc Lanthier, Geneviève Le Templier, Alexandre Mutchmore, Marc-Émile Plourde, Michel Cauchon
{"title":"对于已经抗凝治疗至少6个月的活动性癌症和静脉血栓栓塞患者,与全剂量阿哌沙班相比,减少阿哌沙班的延长治疗在预防复发和降低出血风险方面是否有效?]","authors":"Luc Lanthier, Geneviève Le Templier, Alexandre Mutchmore, Marc-Émile Plourde, Michel Cauchon","doi":"10.1016/j.revmed.2025.06.011","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":94122,"journal":{"name":"La Revue de medecine interne","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[In patients with active cancer and venous thromboembolism who have been anticoagulated for at least 6 months, is extended treatment with a reduced dose of apixaban effective in preventing recurrences and reducing the risk of bleeding, compared to a full dose?]\",\"authors\":\"Luc Lanthier, Geneviève Le Templier, Alexandre Mutchmore, Marc-Émile Plourde, Michel Cauchon\",\"doi\":\"10.1016/j.revmed.2025.06.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":94122,\"journal\":{\"name\":\"La Revue de medecine interne\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"La Revue de medecine interne\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.revmed.2025.06.011\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"La Revue de medecine interne","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.revmed.2025.06.011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
[In patients with active cancer and venous thromboembolism who have been anticoagulated for at least 6 months, is extended treatment with a reduced dose of apixaban effective in preventing recurrences and reducing the risk of bleeding, compared to a full dose?]